Cyclin dependent kinases in cancer

References

• Diaz-Padilla I, Siu LL, Duran I. Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs 2009; 27:586 - 94; http://dx.doi.org/10.1007/s10637-009-9236-6; PMID: 19262992
   PubMed Web of Science ®Google Scholar
• Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73 - 87; PMID: 11960696
   PubMed Web of Science ®Google Scholar
• Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002; 8:Suppl S32 - 7; http://dx.doi.org/10.1016/S1471-4914(02)02308-0; PMID: 11927285
   PubMed Web of Science ®Google Scholar
• Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell 2008; 14:159 - 69; http://dx.doi.org/10.1016/j.devcel.2008.01.013; PMID: 18267085
   PubMed Web of Science ®Google Scholar
• Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8:547 - 66; http://dx.doi.org/10.1038/nrd2907; PMID: 19568282
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30:630 - 41; http://dx.doi.org/10.1016/j.tibs.2005.09.005; PMID: 16236519
   PubMed Web of Science ®Google Scholar
• Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, et al. Cyclin E ablation in the mouse. Cell 2003; 114:431 - 43; http://dx.doi.org/10.1016/S0092-8674(03)00645-7; PMID: 12941272
   PubMed Web of Science ®Google Scholar
• Bagella L, Sun A, Tonini T, Abbadessa G, Cottone G, Paggi MG, et al. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 2007; 26:1829 - 39; http://dx.doi.org/10.1038/sj.onc.1209987; PMID: 17043661
   PubMed Web of Science ®Google Scholar
• Oelgeschläger T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002; 190:160 - 9; http://dx.doi.org/10.1002/jcp.10058; PMID: 11807820
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770 - 83; http://dx.doi.org/10.1200/JCO.2005.03.7689; PMID: 16603719
   PubMed Web of Science ®Google Scholar
• Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 2000; 407:102 - 6; http://dx.doi.org/10.1038/35024111; PMID: 10993082
   PubMed Web of Science ®Google Scholar
• Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010; 29:2325 - 36; http://dx.doi.org/10.1038/onc.2009.510; PMID: 20101221
   PubMed Web of Science ®Google Scholar
• Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene 2005; 24:2909 - 15; http://dx.doi.org/10.1038/sj.onc.1208618; PMID: 15838524
   PubMed Web of Science ®Google Scholar
• Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci 2006; 11:1164 - 88; http://dx.doi.org/10.2741/1871; PMID: 16146805
   PubMed Web of Science ®Google Scholar
• McInnes C. Progress in the evaluation of CDK inhibitors as anti-tumor agents. Drug Discov Today 2008; 13:875 - 81; http://dx.doi.org/10.1016/j.drudis.2008.06.012; PMID: 18639646
   PubMed Web of Science ®Google Scholar
• Cirillo D, Pentimalli F, Giordano A. Peptides or small molecules? Different approaches to develop more effective CDK inhibitors. Curr Med Chem 2011; 18:2854 - 66; http://dx.doi.org/10.2174/092986711796150496; PMID: 21651493
   PubMed Web of Science ®Google Scholar
• Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68:67 - 108; http://dx.doi.org/10.1016/S0065-230X(08)60352-8; PMID: 8712071
   PubMed Web of Science ®Google Scholar
• Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233 - 45; http://dx.doi.org/10.1016/S1535-6108(03)00053-9; PMID: 12676582
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23:9408 - 21; http://dx.doi.org/10.1200/JCO.2005.01.5594; PMID: 16361640
   PubMed Web of Science ®Google Scholar
• Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005; 5:366 - 73; http://dx.doi.org/10.1016/j.coph.2005.04.009; PMID: 15964238
   PubMed Web of Science ®Google Scholar
• Ortega S, Prieto I, Odajima J, Martín A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25 - 31; http://dx.doi.org/10.1038/ng1232; PMID: 12923533
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004; 3:1537 - 42; http://dx.doi.org/10.4161/cc.3.12.1278; PMID: 15539947
   PubMed Web of Science ®Google Scholar
• Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998; 92:3804 - 16; PMID: 9808574
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393 - 7; PMID: 10887097
   PubMed Web of Science ®Google Scholar
• Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50:465 - 72; http://dx.doi.org/10.1007/s00280-002-0527-2; PMID: 12451473
   PubMed Web of Science ®Google Scholar
• Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16:2986 - 99; PMID: 9738567
   PubMed Web of Science ®Google Scholar
• Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003; 14:1270 - 3; http://dx.doi.org/10.1093/annonc/mdg343; PMID: 12881391
   PubMed Web of Science ®Google Scholar
• Burdette-Radoux S, Tozer RG, Lohmann RC, Quirt I, Ernst DS, Walsh W, et al. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22:315 - 22; http://dx.doi.org/10.1023/B:DRUG.0000026258.02846.1c; PMID: 15122079
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7:1590 - 9; PMID: 11410495
   PubMed Web of Science ®Google Scholar
• Liu G, Gandara DR, Lara PN Jr., Raghavan D, Doroshow JH, Twardowski P, et al. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004; 10:924 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-03-0050; PMID: 14871968
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Ilson D, Saltz L, O’Reilly E, Tong W, Maslak P, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19:1985 - 92; PMID: 11283131
   PubMed Web of Science ®Google Scholar
• Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003; 2:549 - 55; PMID: 12813134
   PubMed Web of Science ®Google Scholar
• Fornier MN, Rathkopf D, Shah M, Patil S, O’Reilly E, Tse AN, et al. Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007; 13:5841 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-07-1218; PMID: 17908977
   PubMed Web of Science ®Google Scholar
• Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11:3836 - 45; http://dx.doi.org/10.1158/1078-0432.CCR-04-2651; PMID: 15897584
   PubMed Web of Science ®Google Scholar
• Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11:5935 - 41; http://dx.doi.org/10.1158/1078-0432.CCR-04-2566; PMID: 16115936
   PubMed Web of Science ®Google Scholar
• George S, Kasimis BS, Cogswell J, Schwarzenberger P, Shapiro GI, Fidias P, et al. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer 2008; 9:160 - 5; http://dx.doi.org/10.3816/CLC.2008.n.024; PMID: 18621626
   PubMed Web of Science ®Google Scholar
• Welch S, Hirte HW, Carey MS, Hotte SJ, Tsao MS, Brown S, et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007; 106:305 - 10; http://dx.doi.org/10.1016/j.ygyno.2007.02.018; PMID: 17537491
   PubMed Web of Science ®Google Scholar
• Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60:2108 - 12; PMID: 10786669
   PubMed Web of Science ®Google Scholar
• Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, Sausville EA. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 2000; 18:95 - 107; http://dx.doi.org/10.1023/A:1006313611677; PMID: 10857990
   PubMed Web of Science ®Google Scholar
• Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005; 23:1875 - 84; http://dx.doi.org/10.1200/JCO.2005.03.116; PMID: 15699481
   PubMed Web of Science ®Google Scholar
• Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19:2319 - 33; PMID: 11304786
   PubMed Web of Science ®Google Scholar
• Meijer L, Raymond E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res 2003; 36:417 - 25; http://dx.doi.org/10.1021/ar0201198; PMID: 12809528
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, O’Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96:29 - 37; http://dx.doi.org/10.1038/sj.bjc.6603509; PMID: 17179992
   PubMed Web of Science ®Google Scholar
• Bettayeb K, Sallam H, Ferandin Y, Popowycz F, Fournet G, Hassan M, et al. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther 2008; 7:2713 - 24; http://dx.doi.org/10.1158/1535-7163.MCT-08-0080; PMID: 18790752
   PubMed Web of Science ®Google Scholar
• Müller-Tidow C, Metzger R, Kügler K, Diederichs S, Idos G, Thomas M, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61:647 - 53; PMID: 11212263
   PubMed Web of Science ®Google Scholar
• Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol 2005; 15:319 - 26; http://dx.doi.org/10.1016/j.semcancer.2005.04.007; PMID: 16043362
   PubMed Web of Science ®Google Scholar
• Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008; 26:59 - 65; http://dx.doi.org/10.1007/s10637-007-9090-3; PMID: 17938863
   PubMed Web of Science ®Google Scholar
• Siemeister G, Luecking U, Wagner C, Detjen K, Mc Coy C, Bosslet K. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother 2006; 60:269 - 72; http://dx.doi.org/10.1016/j.biopha.2006.06.003; PMID: 16887322
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3:1427 - 38; PMID: 15542782
   PubMed Web of Science ®Google Scholar
• Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res 2008; 68:5519 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-07-6404; PMID: 18632601
   PubMed Web of Science ®Google Scholar
• McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol 2011; 152:420 - 32; http://dx.doi.org/10.1111/j.1365-2141.2010.08427.x; PMID: 21223249
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23:6333 - 8; http://dx.doi.org/10.1200/JCO.2005.05.021; PMID: 16155016
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104:607 - 18; http://dx.doi.org/10.1182/blood-2004-01-0037; PMID: 15090448
   PubMed Web of Science ®Google Scholar
• Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005; 65:11345 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-05-2159; PMID: 16357141
   PubMed Web of Science ®Google Scholar
• Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106:1042 - 7; http://dx.doi.org/10.1182/blood-2005-01-0320; PMID: 15827128
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S, et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009; 23:961 - 70; http://dx.doi.org/10.1038/leu.2008.378; PMID: 19151776
   PubMed Web of Science ®Google Scholar
• Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8:3527 - 38; PMID: 12429644
   PubMed Web of Science ®Google Scholar
• MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A, et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005; 65:5399 - 407; http://dx.doi.org/10.1158/0008-5472.CAN-05-0233; PMID: 15958589
   PubMed Web of Science ®Google Scholar
• Cirstea D, Hideshima T, Pozzi S, Vallet S, Ikeda H, Santo L, et al. RGB 286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death through Abrogation of CDK Dependent and Independent Survival Mechanisms. [ASH Annual Meeting Abstracts] Blood 2008; 112:2759
   Google Scholar
• Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004; 29:95 - 102; http://dx.doi.org/10.1016/j.tibs.2003.12.004; PMID: 15102436
   PubMed Web of Science ®Google Scholar
• Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008; 51:4986 - 99; http://dx.doi.org/10.1021/jm800382h; PMID: 18656911
   PubMed Web of Science ®Google Scholar
• Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 2009; 8:324 - 32; http://dx.doi.org/10.1158/1535-7163.MCT-08-0890; PMID: 19174555
   PubMed Web of Science ®Google Scholar
• Cirstea D, Vallet S, Raje N. Future novel single agent and combination therapies. Cancer J 2009; 15:511 - 8; http://dx.doi.org/10.1097/PPO.0b013e3181c51c8e; PMID: 20010171
   PubMed Web of Science ®Google Scholar